Clinical studies have shown that serum SAA levels are elevated two to threefold in patients with NASH compared to age-matched healthy controls [173], a finding corroborated by similar increases in Saa expression in murine models of NAFLD [69, 92]. The gene discussed is SAA2; the disease is metabolic dysfunction-associated steatohepatitis.